C12N 2720/12032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2720/12032 (Use of virus as therapeutic agent, other than vaccine) appears on 25 US grants and 38 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 38
- Assignees
- 11
- Inventors
- 41
- Latest grant
- 5 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 2 |
| 2004 | 2 | 2 |
| 2005 | 0 | 4 |
| 2006 | 2 | 2 |
| 2007 | 1 | 1 |
| 2008 | 3 | 2 |
| 2009 | 0 | 3 |
| 2010 | 1 | 2 |
| 2011 | 2 | 4 |
| 2012 | 1 | 2 |
| 2013 | 3 | 2 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 2 |
| 2019 | 1 | 1 |
| 2020 | 3 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Recombinant oncolytic viruses for treatment of metastatic cancers5 Aug 2025US 12,378,289 B2Entos Pharmaceuticals Inc.
- Avian oncolytic virus having modified sequences and uses thereof10 Nov 2020US 10,829,786 B2ARV Pharma Inc.
- Attenuated reovirus2 Jun 2020US 10,668,119 B2Virocure, Inc.
- Oncolytic virus formulation and preparation method thereof4 Feb 2020US 10,548,853 B2Hubei Soundny Biotechnology Co., Ltd.
- Attenuated reoviruses for selection of cell populations6 Aug 2019US 10,369,171 B2Virocure, Inc.
- Novel modified reovirus and use thereof8 Feb 2024US 2024/0041959 A1Virocure, Inc.
- Pharmaceutical formulation comprising a combination of recombinant newcastle disease viruses for the treatment of cancer11 May 2023US 2023/0147975 A1
- Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs23 Jun 2022US 2022/0193220 A1
- T cell repertoire dynamics and oncolytic viral therapy7 Apr 2022US 2022/0105143 A1
- Avian oncolytic virus having modified sequences and uses thereof18 Jun 2020US 2020/0190538 A1ARV Pharma Inc.
Most cited
By later US patents
- Reovirus for the treatment of cellular proliferative disorders56US 6,136,307 AOncolytics Biotech Inc. · 2000
- Method of producing infectious reovirus22US 6,528,305 B2Oncolytics Biotech Inc. · 2003
- Reovirus for the treatment of cellular proliferative disorders19US 6,455,038 B1Oncolytics Biotech Inc. · 2002
- Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions13US 6,994,858 B2Oncolytics Biotech Inc. · 2006
- Method of producing infectious reovirus13US 7,049,127 B2Oncolytics Biotech Inc. · 2006